Skip to main content
SpringerLink
Log in

Fulvestrant: a guide to its use in hormone receptor-positive metastatic breast cancer in postmenopausal women in the EU

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Fulvestrant (Faslodex®), an estrogen receptor antagonist, is indicated for the treatment of postmenopausal women with estrogen receptor-positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on therapy with an anti-estrogen. In this patient population, a fulvestrant 500 mg regimen is more effective in prolonging the time to disease progression than a fulvestrant 250 mg regimen and is generally well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. International Agency for Research on Cancer. GLOBOCAN 2008: cancer fact sheet. 2008. http://globocan.iarc.fr/factsheets/cancers/breast.asp. Accessed 20 Oct 2013.

  2. Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vi11–9.

    Article  Google Scholar 

  3. Peto R. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years [letter]. Lancet. 2000;355(9217):1822.

    Article  CAS  PubMed  Google Scholar 

  4. Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76(1):27–36.

    Article  CAS  PubMed  Google Scholar 

  5. Suzuki T, Miki Y, Nakamura Y, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer. 2005;12(4):701–20.

    Article  CAS  PubMed  Google Scholar 

  6. Baumann CK, Castiglione-Gertsch M. Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer. Drugs. 2007;67(16):2335–53.

    Article  CAS  PubMed  Google Scholar 

  7. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer (version 3.2013). http://www.nccn.com. Accessed 24 Oct 2013.

  8. Bundred N, Howell A. Fulvestrant (Faslodex): current status in the therapy of breast cancer. Expert Rev Anticancer Ther. 2002;2(2):151–60.

    Article  CAS  PubMed  Google Scholar 

  9. Milano A, Dal Lago L, Sotiriou C, et al. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer. 2006;42(16):2692–705.

    Article  CAS  PubMed  Google Scholar 

  10. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001;28(3):291–304.

    Article  CAS  PubMed  Google Scholar 

  11. Croxtall JD, McKeage K. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs. 2011;71(3):363–80.

    Article  CAS  PubMed  Google Scholar 

  12. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600.

    Article  PubMed  Google Scholar 

  13. Garnett SA, Martin M, Jerusalem G, et al. Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Res Treat. 2013;138(1):149–55.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg versus 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2013;. doi:10.1093/jnci/djt337 [Epub 7 Dec 2013].

    PubMed  Google Scholar 

  15. Faslodex® (fulvestrant) 250 mg injectable solution: procedural steps taken and scientific information after authorisation. London: European Medicines Agency; 2013.

  16. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867–73.

    CAS  PubMed  Google Scholar 

  17. Buzdar AU, Robertson JF. Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer. Ann Pharmacother. 2006;40(9):1572–83.

    Article  CAS  PubMed  Google Scholar 

  18. Wakeling AE, Bowler J. Steroidal pure antioestrogens. J Endocrinol. 1987;112(3):R7–10.

    Article  CAS  PubMed  Google Scholar 

  19. Fawell SE, White R, Hoare S, et al. Inhibition of oestrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA. 1990;87:6883–7.

    Article  CAS  PubMed  Google Scholar 

  20. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993;106:1377–88.

    CAS  PubMed  Google Scholar 

  21. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7α-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17 β-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001;61(18):6739–46.

    CAS  PubMed  Google Scholar 

  22. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995;87:746–50.

    Article  CAS  PubMed  Google Scholar 

  24. Faslodex® (fulvestrant) 250 mg injectable solution: EU summary of product characteristics. London: European Medicines Agency; 2013.

  25. Ohno S, Rai Y, Iwata H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results of a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21(12):2342–7.

    Article  CAS  PubMed  Google Scholar 

  26. Pritchard KI, Rolski J, Papai Z, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010;123(2):453–61.

    Article  CAS  PubMed  Google Scholar 

  27. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16):3396–403.

    Article  CAS  PubMed  Google Scholar 

  28. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386–95.

    Article  CAS  PubMed  Google Scholar 

  29. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98(2):229–38.

    Article  CAS  PubMed  Google Scholar 

  30. Warm M, Kates R, Overkamp F, et al. Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients. Breast Cancer Res Treat. 2010;125(1):127–36.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The manuscript was reviewed by: M. Daouphars, Centre Henri Becquerel, Rouen, France; E. Obarcanin, Sarajevo, Bosnia and Herzegovina; G. G. Steger, Medical University of Vienna, Department of Internal Medicine I, Division of Oncology, Vienna, Austria.

Disclosure

This article was updated from Drugs 2011;71(3):364-80 [11]. The preparation of these reviews was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Lesley J. Scott, Jamie D. Croxtall & Kate McKeage

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jamie D. Croxtall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kate McKeage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., Croxtall, J.D. & McKeage, K. Fulvestrant: a guide to its use in hormone receptor-positive metastatic breast cancer in postmenopausal women in the EU. Drugs Ther Perspect 30, 42–47 (2014). https://doi.org/10.1007/s40267-013-0098-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-013-0098-9

Keywords

Search

Navigation